Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and Drug Administration (FDA).
Korea Joongang Daily on MSN4h
Celltrion's Actemra biosimilar gets FDA approvalCelltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.
As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
South Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Takeda that will expand its expertise with small ...
Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 Company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback